Evaluation of hematoporphyrin photoradiation therapy to treat choroidal melanomas.
Hematoporphyrin derivative-photoradiation therapy (HPD-PRT) was used to treat choroidal melanomas in 23 human subjects. Tumor sizes were divided into three categories: less than 500 mm3 (11 patients), 500-1,000 mm3 (four patients), and greater than 1,000 mm3 (eight patients). Tumors were exposed to 630 nm laser light at total doses of 300-3,000 J/cm2. Significant tumor reduction was noted in the subjects with initial tumor volume of less than 500 mm3 and 500-1,000 mm3.
D002830:Choroid Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D017324:Hematoporphyrin Derivative; D006415:Hematoporphyrins / Q000627:therapeutic use*; D006801:Humans; D053685:Laser Therapy; D008545:Melanoma / Q000188:drug therapy* / Q000503:physiopathology; D010778:Photochemotherapy; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D014792:Visual Acuity
D006415:Hematoporphyrins; D011838:Radiation-Sensitizing Agents; D017324:Hematoporphyrin Derivative